KOSDAQBiotech & Pharma078160

Medipostco

₩7,930▲ 5.87%2026-11-18 close
Market Cap
₩310.9B
Turnover
₩200M
Volume
30K
Shares out.
39.2M
PER
—
PBR
1.2×
EPS
-₩1,045
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Cartistem Trials Expand as Losses Persist

Medipostco is concentrating spending on Cartistem's US Phase 3 trial and Japan approval preparation, and has recorded losses for five consecutive quarters through the third quarter of 2026.

  1. 1

    Revenue grew from KRW 64.2 billion in 2022 to KRW 73.7 billion in 2025, rising for three consecutive years from 2023, while the operating loss widened from KRW 17.4 billion to KRW 68 billion.

  2. 2

    Third-quarter 2026 revenue was KRW 19.2 billion, up 2.8% year on year, while the operating loss widened to KRW 19.8 billion from KRW 14.1 billion a year earlier.

  3. 3

    Consolidated revenue for the first three quarters of 2026, disclosed on November 16, 2026, was KRW 57.5 billion, with an operating loss of KRW 61 billion.

  4. 4

    The US Phase 3 trial began dosing its first patient in July 2026 and will enroll 300 patients with knee osteoarthritis for a two-year follow-up.

  5. 5

    Japan's Phase 3 trial met its primary and secondary efficacy endpoints as announced in May 2026, and the company targets a filing by year-end 2026 and approval within 2027.

02

Business structure

Medipostco is a biotech company whose core product is Cartistem, an umbilical cord blood-derived allogeneic mesenchymal stem cell therapy. Cartistem was approved in Korea in 2012 for knee osteoarthritis, and the company says cumulative procedures have exceeded about 36,000. The business runs along three lines.

The first is the existing domestic supply of Cartistem, the second is a newer regenerative medicine business covering umbilical tissue, fat and immune cell storage, and the third is global commercialization aimed at the United States and Japan, where clinical and approval preparation costs were heavily reflected in third-quarter 2026 results.

In Japan, the company signed an exclusive distribution agreement with Teikoku Pharma in December 2025, including an upfront payment and short-term regulatory milestones totaling KRW 26.4 billion. Teikoku Pharma is regarded as a leader in orthopedics in Japan, with annual sales reported at about KRW 450 billion.

On the manufacturing side, the company is switching to a domestically developed chemically defined medium from Excel Therapeutics in response to tighter overseas regulation, and it says this material accounts for 10 to 15 percent of treatment cost.

In 2026 the company appointed Ho-sung Min as CEO to oversee the US and Japan subsidiaries, overseas clinical trials and business development.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩18.7B-₩14.1B−75.3%
2025Q4₩17.9B-₩21.3B−118.7%
2026Q1₩19.5B-₩16.9B−86.6%
2026Q2₩18.8B-₩24.3B−129.6%
2026Q3₩19.2B-₩19.8B−103.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩64.2B-₩17.4B₩3.1B−27.1%1.7%117.9%
2023₩68.6B-₩25.1B₩5.8B−36.6%1.9%43.3%
2024₩70.7B-₩48.5B-₩62.5B−68.7%−24.9%64.0%
2025₩73.7B-₩68B-₩85.4B−92.3%−34.3%72.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a DART-filed annual basis, revenue rose from KRW 64.2 billion in 2022 to KRW 68.6 billion in 2023 (up 6.9% year on year), KRW 70.7 billion in 2024 (up 2.9%) and KRW 73.7 billion in 2025 (up 4.2%).

Revenue rose for three consecutive years from 2023 through 2025, and 2025 was the largest year of the 2022 to 2025 period.

Over the same span the operating loss was KRW 17.4 billion in 2022, KRW 25.1 billion in 2023, KRW 48.5 billion in 2024 and KRW 68 billion in 2025, a continuing loss with widening deficits, and the company has posted operating losses for four consecutive years from 2022 through 2025.

The operating margin fell from -27.1% in 2022 to -36.6% in 2023, -68.7% in 2024 and -92.3% in 2025. The 4.2% revenue growth in 2025 did not keep pace with the increase in operating loss from KRW 48.5 billion to KRW 68 billion.

Net income attributable to controlling shareholders was KRW 3.07 billion in 2022 and KRW 5.84 billion in 2023 (up 90.3%), before turning to a net loss of KRW 62.5 billion in 2024 and widening to a net loss of KRW 85.4 billion in 2025.

Net income including non-controlling interests, which is a different figure, was KRW 2.11 billion in 2022, KRW 4.95 billion in 2023, a net loss of KRW 63.4 billion in 2024 and a net loss of KRW 86 billion in 2025.

Operating cash flow was negative KRW 6.19 billion in 2022 and widened to negative KRW 57.1 billion in 2025.

The debt ratio fell from 117.9% in 2022 to 43.3% in 2023 before rising to 72.7% in 2025, when total equity was KRW 249.9 billion, equity attributable to controlling shareholders was KRW 249 billion and total liabilities were KRW 181.6 billion.

Quarterly operating losses were KRW 14.1 billion in the third quarter of 2025, KRW 21.3 billion in the fourth quarter, KRW 16.9 billion in the first quarter of 2026, KRW 24.3 billion in the second quarter and KRW 19.8 billion in the third quarter, which makes five consecutive loss-making quarters.

In the second quarter of 2026 the company swung to net income attributable to controlling shareholders of KRW 32.3 billion despite an operating loss of KRW 24.3 billion, so the composition of non-operating items is central to reading that quarter.

The combined net loss attributable to controlling shareholders over the last four quarters was KRW 42.2 billion.

05

Industry analysis

Knee osteoarthritis treatment has many existing therapies focused on symptom relief, so Cartistem positions itself on a disease-modifying approach aimed at cartilage regeneration.

The US FDA typically requires two or more independent Phase 3 trials for a new drug approval, while Medipostco secured agreement on a single pivotal design based on domestic real-world evidence and Korean and Japanese trial results.

The company says this agreement cut the US Phase 3 enrollment from 600 to 300 patients, shortens the trial period by three to six months and is expected to reduce costs by 20 to 30 percent.

In Japan, Teikoku Pharma will handle distribution, which is a way to speed market entry rather than building a sales force from scratch. Cell therapies have approval requirements and manufacturing standards that differ by product, so changes in the regulatory environment feed directly into development timelines.

Compared with listed Korean biotech companies such as Samsung Biologics and Celltrion, which operate large-scale production and commercial sales systems, Medipostco is still a cell therapy company approaching approval and commercialization.

Teikoku Pharma's annual sales are several times Medipostco's annual revenue, so the partner's sales capability in Japan is a major determinant of the royalty and milestone economics.

06

Outlook

The company has set out three tracks. In Japan, the target is a product approval filing by year-end 2026 and approval within 2027, after which revenue from finished product supply and additional milestones tied to long-term sales can follow.

In the United States, the trial began dosing in July 2026 with 300 patients and two years of follow-up, and after trial completion the company plans to proceed in sequence with the final study report and a Biologics License Application, with a US approval target set for 2031.

In Korea, the company plans to release interim results from real-world evidence on about 560 patients treated more than three years earlier by year-end 2026, and to disclose the future development plan for its SMUP-IA-01 pipeline in the same period.

Management expects US annual demand of around 300,000 vials and sees the peak period at five to ten years out.

On a standalone basis, the company said first-half 2026 revenue was KRW 41.3 billion with an operating profit of KRW 0.7 billion, but how it bridges that with the consolidated operating loss will determine future results.

The next checkpoints are whether the real-world evidence interim results are released, whether the Japan filing is completed and how US Phase 3 enrollment progresses.

07

Valuation

PER
—
PBR
1.2×
ROE
-16.9%
EPS
-₩1,045
BPS
₩6,000
Dividend per share
₩0

Because the company has posted net losses attributable to controlling shareholders over the last four quarters, its price-to-earnings ratio cannot be calculated.

The price-to-book ratio sits above 1x, meaning the share price is set above book value against equity attributable to controlling shareholders of KRW 249 billion at the end of 2025. That premium over net assets can be read as reflecting expectations for US and Japan approvals and overseas sales of Cartistem.

Net income attributable to controlling shareholders was positive only in 2022 and 2023 and negative in 2024 and 2025, so comparisons based on past earnings multiples have limited meaning. The dividend yield is close to zero, so shareholders receive no earnings payout and returns depend on the share price.

With the operating margin having fallen to -92.3% in 2025 and operating losses continuing through the third quarter of 2026, the current premium over book value reflects expectations for profit conversion after approval and commercialization rather than current sales expansion.

For this stock, comparisons against net assets and against pipeline stage are more factual than earnings-based multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

More efficient US trial design

The FDA approved a single pivotal design for Cartistem's US Phase 3 trial, replacing the two independent trials usually required for approval.

According to the company, enrollment was cut from 600 to 300 patients, the trial period is shortened by three to six months and development costs are expected to fall by 20 to 30 percent. The company also points to domestic real-world evidence and Korean and Japanese trial results as the basis for the design.

Japan Phase 3 success and a distribution partner

The Japan Phase 3 trial, which enrolled 130 patients at 13 institutions with 52-week follow-up, met its primary and secondary efficacy endpoints as announced in May 2026.

The exclusive agreement with Teikoku Pharma signed in December 2025 includes an upfront payment and short-term regulatory milestones totaling KRW 26.4 billion. Product supply after approval and milestones linked to sales could become additional revenue streams.

Revenue growth and a standalone profit trend

Consolidated revenue rose for three consecutive years from 2023 through 2025, and third-quarter 2026 revenue was up 2.8% year on year. According to a company press release, first-half 2026 standalone revenue was KRW 41.3 billion, with an operating profit of KRW 0.7 billion. The company also says its newer regenerative medicine storage businesses are broadening its revenue base.

09

Bear factors

Cumulative operating losses widening

Cumulative consolidated operating loss for the first three quarters of 2026 was disclosed at KRW 61 billion. The quarterly operating loss widened from KRW 14.1 billion in the third quarter of 2025 to KRW 19.8 billion in the third quarter of 2026, extending a run of five consecutive loss-making quarters.

The company attributes this to US and Japan clinical and approval costs, but it has not given a figure for when those costs will ease.

Cash burn and rising liabilities

Cash outflow from operating activities has persisted since 2022, which may add to funding pressure. The debt ratio rose from 43.3% in 2023 to 72.7% in 2025, and total liabilities at the end of 2025 were KRW 181.6 billion.

Total equity of KRW 249.9 billion provides a buffer, but if clinical spending continues, additional funding may be required.

Long approval timelines

The target is a Japan filing by year-end 2026 with approval within 2027, and a US approval target of 2031. Delays or additional data requests would extend the loss-making period.

The second-quarter 2026 swing to net income attributable to controlling shareholders ran against an operating loss of KRW 24.3 billion, so it needs to be separated into one-off factors and structural change.

10

Risk factors

Clinical and approval risk

Key questions are whether the single US trial satisfies FDA approval requirements and whether results on the primary endpoints hold across 300 patients. A Japan filing slipping past year-end 2026 would likely push back the 2027 approval target.

The switch to a domestic medium also requires demonstrating comparability during the Japan approval process, which may require additional testing.

Financing risk

Operating cash outflow widened to KRW 57.1 billion in 2025, and the combined net loss attributable to controlling shareholders over the last four quarters was KRW 42.2 billion.

If clinical programs run longer, the need for equity or debt financing could grow against total equity of KRW 249.9 billion and total liabilities of KRW 181.6 billion. Financing terms would directly affect shareholder value.

Commercialization and partner risk

Japan revenue depends heavily on Teikoku Pharma's sales capability and the finished product supply structure. Upfront and regulatory milestone receipts depend on approval timing.

The US annual target of about 300,000 vials will hinge on actual market acceptance after approval, so the gap between management's projection and real sales is a risk.

11

What to watch next

  1. Before December 31, 2026

    Release of interim real-world evidence results for Cartistem in Korea, based on data from about 560 patients treated more than three years earlier, which links to the basis for the US single-trial design.

  2. By December 31, 2026 (company target)

    Filing of the Japan product approval application for Cartistem. Once filed, the review moves toward a 2027 decision, bringing the Teikoku Pharma supply timeline closer.

  3. Before December 31, 2026

    Announcement of the future development plan for the SMUP-IA-01 pipeline, a point at which the research spending structure beyond Cartistem can be gauged.

  4. Around March 31, 2027 (statutory filing deadline)

    Filing of the 2026 annual report, where annual operating loss, operating cash flow and debt ratio can be checked against the DART regular report figures.

  5. Within 2027 (date not fixed)

    Japan approval decision for Cartistem and the start of supply by Teikoku Pharma, where approval timing determines when milestone receipts after the upfront payment and product sales begin.

12

Overall view

Medipostco's revenue rose from KRW 64.2 billion in 2022 to KRW 73.7 billion in 2025, yet the operating loss widened to KRW 68 billion over the same period. Cumulative consolidated operating loss for the first three quarters of 2026 was KRW 61 billion, extending five consecutive loss-making quarters.

A large part of these costs goes to dosing in the US Phase 3 trial of Cartistem and preparing the Japan filing, which the company describes as investment for commercialization.

Strengths include FDA approval of a single pivotal design, success in the Japan Phase 3 trial, the Teikoku Pharma agreement and a standalone profit trend. Weaknesses include the cumulative consolidated loss, a widening operating cash outflow, a rising debt ratio and approval timelines stretching to 2027 and 2031.

For shareholders, dividends are effectively absent, and net income attributable to controlling shareholders has been positive only in 2022 and 2023.

The next checkpoints are the real-world evidence interim results due before year-end 2026, whether the Japan filing is made and the size of the operating loss in the annual report due around March 31, 2027. This report is provided for information only and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. medi-post.co.kr
  2. ajunews.com
  3. hankyung.com
  4. mt.co.kr
  5. news.nate.com
  6. view.asiae.co.kr
  7. view.asiae.co.kr
  8. mt.co.kr
  9. wowtv.co.kr
  10. view.asiae.co.kr
  11. vegannews.co.kr
  12. thepublic.kr
  13. tradingkey.com
  14. paxetv.com
  15. news1.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis